Text Size
- News Releases
- What's New
- 06 Dec
- “Let’s Learn about Cancer Genomic Medicine,” Chugai’s Website for Patients and the General Public, Won the Asakawa Award in the 7th Web GRAND PRIX
- 04 Dec
- R&I Raises Chugai's Issuer Rating from “AA –” to “AA”
- 02 Dec
- Chugai Completes Transfer of Rights to Maruho for Oxarol® Ointment 25µg/g and Oxarol® Lotion 25µg/g, Therapeutic Agents for Keratosis including Psoriasis Vulgaris, and Marduox® Ointment, a Therapeutic Agent for Psoriasis Vulgaris
- 29 Nov
- Results from Phase III SAkuraSky Study for Chugai’s Satralizumab in Neuromyelitis Optica Spectrum Disorder Published in The New England Journal of Medicine Online
- 27 Nov
- Chugai Launches Tecentriq Intravenous Infusion 840 mg as an Optimal Formulation for the Treatment of PD-L1-Positive Inoperable or Metastatic Triple Negative Breast Cancer
Video Introduction of CHUGAI- Share this site
